LIPOVÝ, Břetislav and Marketa HANSLIANOVA. Efficacy of new cephalosporins in treatment of multidrug-resistant strains of gram-negative bacteria in burn patients. Burns. OXFORD: ELSEVIER SCI LTD, 2019, vol. 45, No 7, p. 1724-1725. ISSN 0305-4179. Available from: https://dx.doi.org/10.1016/j.burns.2019.06.005.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Efficacy of new cephalosporins in treatment of multidrug-resistant strains of gram-negative bacteria in burn patients
Authors LIPOVÝ, Břetislav (203 Czech Republic, guarantor, belonging to the institution) and Marketa HANSLIANOVA (203 Czech Republic).
Edition Burns, OXFORD, ELSEVIER SCI LTD, 2019, 0305-4179.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30212 Surgery
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.066
RIV identification code RIV/00216224:14110/19:00112591
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.burns.2019.06.005
UT WoS 000489028200027
Keywords in English multidrug-resistant strains; gram-negative bacteria; cephalosporins
Tags 14110229, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 20/1/2020 07:18.
Abstract
Burn patients are confronted with a variety of potentiallypathogenic microorganisms every day. Although increasingprevalence of micromycetal infections has been observed,especially in the last decade, bacteria remain the dominantpathogens in the etiology of infectious complications in thesepatients. In particular, gram-negative bacteria have a signifi-cant impact on mortality and morbidity of burn patients(Enterobacteriaceae, Pseudomonas aeruginosa). One possibleexplanation is a dramatic increase in resistance of thesepathogens (high prevalence of multidrug resistant–MDR–bacterial strains) and the second possibility is an insufficientamount of available and effective antibiotics (especiallyagainst carbapenem-resistantEnterobacteriaceae—CRE).
PrintDisplayed: 27/8/2024 20:58